A review of olmesartan medoxomil - A new angiotensin II receptor blocker

British Journal of Cardiology

Volumn 12, Issue 2, 2005, Pages 125-129

  Whittaker, Andrew ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Angiotensin II receptor blocker; CS 866; Heart failure; Hypertension; Olmesartan medoxomil; Olmetec

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; RENIN; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANKLE EDEMA; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FACE EDEMA; FLU LIKE SYNDROME; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; PHARMACODYNAMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 17144380790     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Dahlof B et al. The losartan intervention for end-point reduction in hypertension study. Lancet 2002;359:995-1003.
2. Elliott HL. Angiotensin II antagonists: efficacy, duration of action, and comparison with other drugs. J Hum Hypertens 1998; 12 271-4.
3. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
4. Klaus KU, Schmitz H. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist in primary hypertension: a double-blind, placebo-controlled, dose-titration study. Clin Drug Invest 1998;15: 217-27.
5. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19:S49-S56.
6. http://www.takeda.ch/german/cardio/a_blo_rasystem5.htm
7. Benicar® package insert. Sankyo Pharma, Inc, New York, US.
8. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens 2003;21(suppl 2):S43-S46.
9. Laies P, Püchler K, Kirch W. The pharmacokinetics and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19(suppl 1):S21-S32.
10. von Bergmann K, Laeis P, Püchler K et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 suppl 1):S33-S40.
11. Herbert J-M, Delisee C, Dol F et al. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994;251 143-50.
12. de Gasparo M, Whitebread S. Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept 1995;59:303-11.
13. Edwards RM, Aiyar N, Ohlstein EH et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260:175-81.
14. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001;19(suppl 1):S15-S20.
15. Püchler K, Laeis P, Gunther A et al. Safety, tolerability and efficacy of the new oral angiotensin II (AT1)-receptor antagonist CS-866 in patients with mild to moderate hypertension. J Hum Hypertens 1999;13(suppl 3):S4.
16. Masonson HN, Punzi HA, Neutel JM et al. CS-866 (angiotensin II receptor antagonist): a double blind study using ambulatory blood pressure monitoring in hypertensive patients. Am J Hypertens 1998;11:77A.
17. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;8(suppl):37C-43C.
18. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3 283-91.
19. Israili ZH, Hall WD. Cough and angioneurotic oedema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992; 117 234-42.
20. Van Mieghem W. A multicentre, double-blind, efficacy, toterability, and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension. J Hypertens 2001;19(suppl 2):152 [Abstract].
21. Püchler K, Laeis P, Stumpe KO. A comparison of the efficacy and safety of the oral angiotensin II antagonist olmesartan medoxomil with those of atenolol in patients with moderate to severe hypertension under continuous treatment with hydrochlorothiazide. J Hypertens 2001;19(suppl 2):153 [Abstract].
22. Williams PA. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension. J Hypertens 2001;19(suppl 2):300.
23. Chrysant SG, Marbury TC, Robinson TD. The antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17 425-32.
24. Ball K. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension. J Hypertens 2001;19(suppl 2):153 [Abstract].
25. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexitil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003;23:419-30.
26. British National Formulary. London British Medical Association, 2003.
27. Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6.